(S)-1-Boc-3-羟甲基哌啶 | 140695-84-7

• 物质功能分类: 有机原料 - 杂环化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: (S)-1-Boc-3-羟甲基哌啶
• 中文别名: (S)-1-BOC-3缭疟圲哺嗌V；(S)-1-N-Boc-3-羟甲基哌啶；(S)-1-叔丁氧羰基-3-羟甲基哌啶；S-1-Boc-3-羟甲基哌啶；(S)-1-N-Boc-3-(羟甲基)哌啶；(S)-1-Boc-3-(羟甲基)哌啶；(S)-1-B0C-3羟甲基哌啶；(S)-N-BOC-3-哌啶甲醇；(S)-N-BOC-3-羟甲基哌啶；(S)-叔丁基3-(羟甲基)哌啶-1-羧酸酯；(S-1-BOC-3-羟甲基哌；S-BOC-3-哌啶甲醇
• 英文名称: tert-butyl (3S)-3-(hydroxymethyl)piperidine-1-carboxylate
• 英文别名: tert-butyl (S)-3-(hydroxymethyl)piperidine-1-carboxylate；(S)-tert-butyl 3-(hydroxymethyl)piperidine-1-carboxylate；(S)-N-(tert-butoxycarbonyl)-3-hydroxymethylpiperidine；(S)-1-Boc-3-(Hydroxymethyl)Piperidine
• CAS: 140695-84-7
• 化学式: C₁₁H₂₁NO₃
• mdl: MFCD03094733
• 分子量: 215.293
• InChiKey: OJCLHERKFHHUTB-VIFPVBQESA-N

物化性质

• 熔点：
  96-98 °C
• 沸点：
  308.0±15.0 °C(Predicted)
• 密度：
  1.059±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.91
• 拓扑面积：
  49.8
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险品标志：
  Xi
• 危险类别码：
  R36/37/38
• 海关编码：
  2942000000
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335
• 储存条件：
  室温

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
tert-butyl (3S)-3-(hydroxymethyl)piperidine-1-carboxylate
Product Name:
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H315: Causes skin irritation
H319: Causes serious eye irritation
H335: May cause respiratory irritation
P261: Avoid breathing dust/fume/gas/mist/vapours/spray
Wear protective gloves/protective clothing/eye protection/face protection
P280:
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing
P304+P340: IF INHALED: Remove victim to fresh air and keep at rest in a position comfortable for breathing
P405: Store locked up

---

Section 3. Composition/information on ingredients.
tert-butyl (3S)-3-(hydroxymethyl)piperidine-1-carboxylate
Ingredient name:
CAS number: 140695-84-7

---

Section 4. First aid measures
Immediately wash skin with copious amounts of water for at least 15 minutes while removing
Skin contact:
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.
Ingestion:

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Not specified
Appearance:
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C11H21NO3
Molecular weight: 215.3

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  (S)-1-Boc-3-羟甲基哌啶 在 三乙酰氧基硼氢化钠 、 三苯基膦 、 偶氮二甲酸二乙酯 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 26.5h， 生成 2-((S)-1-isopropylpiperidin-3-ylmethyl)isoindole-1,3-dione
  参考文献：
  名称：

  [EN] PIPERIDINE AMIDES AS MODULATORS OF THE GHRELIN RECEPTOR
  [FR] PIPÉRIDINE-AMIDES EN TANT QUE MODULATEURS DU RÉCEPTEUR DE LA GHRÉLINE

  摘要：

  化合物的结构式（I）或其药学上可接受的盐，可用于治疗糖尿病和肥胖。

  公开号：

  WO2011117254A1
• 作为产物：
  描述：

  3-哌啶甲醇 在 lipase P from Pseudomonas fluorescens 作用下， 以 甲基叔丁基醚 为溶剂， 反应 7.0h， 生成 (S)-1-Boc-3-羟甲基哌啶
  参考文献：
  名称：

  Chemical and Enzymatic Resolution of (R,S)-N-(tert-Butoxycarbonyl)-3-hydroxymethylpiperidine

  摘要：

  (S)-N-(tert-Butoxycarbonyl)-3-hydroxymethylpiperidine 1 was made from (R,S)-3-hydroxymethylpiperidine 2 via fractional crystallization of the corresponding L(-)-dibenzoyl tartarate salt 3 followed by hydrolysis and acylation. Lipase from Pseudomonas cepacia was found to be the best enzyme for the stereospecific resolution of (RS)-N-(tert-butoxycarbonyl)-3-hydroxymethylpiperidine 4. (S)-N-(tert-Butoxycarbonyl)-3-hydroxymethylpiperidine I was obtained in 16% yield and >95% enantiomeric excess (ee) by hydrolysis of (R,S)-acetate 5 by lipase PS from Pseudomonas cepacia. Lipase PS-catalyzed esterification of the (RS)-N-(tert-butoxycarbonyl)-3-hydroxymethylpiperidine 4 with succinic anhydride provided the S-hemisuccinate ester 6, which could be easily separated and hydrolyzed by base to the (S)-N-(tert-butoxycarbonyl)-3-hydroxymethylpiperidine 1. The yield and ee could be improved greatly by repetition of the process. Using the repeated esterification procedure(S)-N-(tert-butoxycarbonyl)-3-hydroxymethylpiperidine I was obtained in 32% yield (maximum theoretical yield 50%) and 98.9% ee.

  DOI：

  10.1021/op010210b

文献信息

• SUBSTITUTED BIPIPERIDINYL DERIVATIVES
  申请人：Bayer Pharma Aktiengesellschaft

  公开号：US20160318866A1

  公开（公告）日：2016-11-03

  The invention relates to novel substituted bipiperidinyl derivatives, to processes for their preparation, to their use for the treatment and/or prevention of diseases and to their use for preparing medicaments for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of diabetic microangiopathies, diabetic ulcers on the extremities, in particular for promoting wound healing of diabetic foot ulcers, diabetic heart failure, diabetic coronary microvascular heart disorders, peripheral and cardiac vascular disorders, thromboembolic disorders and ischaemias, peripheral circulatory disturbances, Raynaud's phenomenon, CREST syndrome, microcirculatory disturbances, intermittent claudication, and peripheral and autonomous neuropathies.

  该发明涉及新型取代的双哌啶衍生物，涉及它们的制备方法，涉及它们用于治疗和/或预防疾病以及用于制备治疗和/或预防疾病的药物的用途，特别是用于治疗和/或预防糖尿病微血管病变、四肢糖尿病溃疡，特别是促进糖尿病足溃疡愈合、糖尿病心力衰竭、糖尿病冠状微血管心脏疾病、外周和心脏血管疾病、血栓栓塞疾病和缺血、外周循环障碍、雷诺现象、CREST综合征、微循环障碍、间歇性跛行以及外周和自主神经病变的治疗和/或预防。
• Beta lactam compounds and their use as inhibitors of tryptase
  申请人：Bristol-Myers Squibb Co.

  公开号：US06335324B1

  公开（公告）日：2002-01-01

  Compounds of the formulas: are disclosed. These compounds inhibit tryptase as well as other enzyme systems or are selective tryptase inhibitors and are useful as antiinflammatory agents particularly in the treatment of chronic asthma.

  这些化合物的结构式已被披露。这些化合物抑制色胺酸蛋白酶以及其他酶系统，或者是选择性色胺酸蛋白酶抑制剂，并且在特别是治疗慢性哮喘方面作为抗炎药物是有用的。
• [EN] GCN2 INHIBITORS AND USES THEREOF<br/>[FR] INHIBITEURS DE GCN2 ET LEURS UTILISATIONS
  申请人：MERCK PATENT GMBH

  公开号：WO2019148132A1

  公开（公告）日：2019-08-01

  The present invention provides compounds, compositions thereof, and methods of using the same.

  本发明提供了化合物、其组合物以及使用它们的方法。
• Novel farnesyl protein transferase inhibitors as antitumor agents
  申请人：Schering Corporation

  公开号：US20040122018A1

  公开（公告）日：2004-06-24

  Disclosed are novel tricyclic compounds represented by the formula (1.0): 1 and a pharmaceutically acceptable salt or solvate thereof. The compounds are useful for inhibiting farnesyl protein transferase. Also disclosed are pharmaceutical compositions comprising compounds of formula 1.0. Also disclosed are methods of treating cancer using the compounds of formula 1.0.

  揭示了由式（1.0）表示的新型三环化合物： 1 及其药学上可接受的盐或溶剂。这些化合物对于抑制法尼西基蛋白转移酶是有用的。还揭示了包括式1.0化合物的药物组合物。还揭示了使用式1.0化合物治疗癌症的方法。
• Zn-Catalyzed<i>tert</i>-Butyl Nicotinate-Directed Amide Cleavage as a Biomimic of Metallo-Exopeptidase Activity
  作者：Clarence C. D. Wybon、Carl Mensch、Charlie Hollanders、Charlène Gadais、Wouter A. Herrebout、Steven Ballet、Bert U. W. Maes

  DOI：10.1021/acscatal.7b02599

  日期：2018.1.5

  A two-step catalytic amide-to-ester transformation of primary amides under mild reaction conditions has been developed. A tert-butyl nicotinate (tBu nic) directing group is easily introduced onto primary amides via Pd-catalyzed amidation with tert-butyl 2-chloronicotinate. A weak base (Cs2CO3 or K2CO3) at 40–50 °C can be used provided that 1,1′-bis(dicyclohexylphosphino)ferrocene is selected as ligand

  已经开发了在温和的反应条件下伯酰胺的两步催化酰胺转化为酯的方法。甲叔丁基烟酸甲酯（吨卜NIC）指示组很容易通过Pd催化的酰胺化与引入到伯酰胺叔丁基2-氯烟。如果选择1,1'-双（二环己基膦基）二茂铁作为配体，则可以使用40–50°C的弱碱（Cs 2 CO 3或K 2 CO 3）。所述吨卜NIC活化酰胺随后允许的Zn（OAc）2催化的醇解nonsolvolytic在吨在中性反应条件下于40–60°C的BuOAc。激活机制是仿生的：在引导基团中吡啶的C3酯取代基构成了适合Zn螯合的反式构象异构体，C═O酰胺-Zn-N引导基团，并且Zn配位醇还被激活为亲核试剂通过氢键与催化剂的乙酸酯配体键合。另外，乙酸盐配体有助于分子内O至N质子转移。化学选择性相对于其他官能团以及与具有挑战性的反应伙伴（如肽，糖和固醇）的相容性说明了这种两步酰胺裂解方法的合成适用性。该Ť卜NIC酰胺在裂解前不需要纯化。初步实验